Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.7%

2 terminated/withdrawn out of 35 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 28 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
32(91.4%)
Early Phase 1
3(8.6%)
35Total
Phase 1(32)
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT07078695Phase 1Active Not Recruiting

A Trial of SHR-1139 in Healthy Volunteers

Role: lead

NCT07390747Phase 1Recruiting

A Trial of SHR-2173 in Healthy Volunteers

Role: lead

NCT07358377Phase 1Not Yet Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor

Role: lead

NCT07238647Early Phase 1Recruiting

A Trial of HRS-5817 in Obese Participants

Role: lead

NCT06830850Phase 1Recruiting

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT07033455Early Phase 1Completed

A Trial of HRS-1893 in Healthy Volunteers

Role: lead

NCT04446260Phase 1Completed

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Role: collaborator

NCT06114745Phase 1Completed

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Role: lead

NCT06559007Phase 1Completed

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

Role: lead

NCT06560138Phase 1Withdrawn

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT06519981Early Phase 1Completed

Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

Role: lead

NCT05594875Phase 1Completed

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Role: lead

NCT05082545Phase 1Completed

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Role: lead

NCT04800263Phase 1Completed

A Trial of SHR-1905 in Healthy Subjects

Role: lead

NCT05638347Phase 1Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Role: lead

NCT04324814Phase 1Completed

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Role: lead

NCT03208959Phase 1Completed

A Trial of HTI-1090 in Subjects With Advanced Solid Tumors

Role: lead

NCT02759640Phase 1Completed

A Phase I Trial of HS-10241 in Solid Tumors

Role: lead

NCT04333134Phase 1Completed

A Trial of SHR3162 in Healthy Caucasian Volunteers

Role: lead

NCT04301804Phase 1Completed

A Trial of SHR6390 in Healthy Caucasian Volunteers

Role: lead